{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Proportion of patients with particular genetic abnormalities, including DNA Methyltransferase 1 (DNMT1) depletion, detected by whole exome sequencing correlation with clinical response","groups":[{"description":"INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \\< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.\n\nflow cytometry: Correlative studies\n\nDNA methylation analysis: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ndecitabine: Given subcutaneously\n\nmicroarray analysis: Correlative studies\n\ngene expression analysis: Correlative studies\n\npharmacological study: Correlative studies\n\npolymorphism analysis: Correlative studies","id":"OG000","title":"Arm I: Decitabine 0.2mg/kg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Proportion of Patients With Particular Genetic Abnormalities Detected by Whole Exome Sequencing Correlation With Clinical Response","type":"SECONDARY","unitOfMeasure":"participants"}